Spots Global Cancer Trial Database for acute myeloid leukemia refractory
Every month we try and update this database with for acute myeloid leukemia refractory cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia | NCT06017258 | Refractory Acut... Relapsed Acute ... Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... | CD371-YSNVZ-IL1... | 1 Year - | Memorial Sloan Kettering Cancer Center | |
| A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML | NCT03690154 | Advanced Cancer Solid Tumors Acute Myeloid L... Acute Myeloid L... | FN-1501 | 18 Years - | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | |
| Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) | NCT05546580 | Acute Myeloid L... Acute Myeloid L... | Iadademstat Gilteritinib Or... | 18 Years - | Oryzon Genomics S.A. | |
| Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) | NCT05546580 | Acute Myeloid L... Acute Myeloid L... | Iadademstat Gilteritinib Or... | 18 Years - | Oryzon Genomics S.A. | |
| CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT06128044 | Acute Myeloid L... Acute Myeloid L... | CB-012 | 18 Years - | Caribou Biosciences, Inc. | |
| CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT06128044 | Acute Myeloid L... Acute Myeloid L... | CB-012 | 18 Years - | Caribou Biosciences, Inc. | |
| Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia | NCT05574608 | Acute Myeloid L... Acute Myeloid L... | CD123-CAR-NK ce... | 18 Years - | Affiliated Hospital to Academy of Military Medical Sciences | |
| Natural Killer-cell Therapy for Acute Myeloid Leukemia | NCT04347616 | Acute Myeloid L... Acute Myeloid L... | UCB-NK cells IL-2 | 18 Years - | Radboud University Medical Center | |
| CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | NCT05854966 | Acute Myeloid L... Acute Myeloid L... Granulocytic Sa... | CPI 613 Metformin Blood draws Bone marrow bio... | 18 Years - | Wake Forest University Health Sciences | |
| Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 | NCT05949125 | Acute Myeloid L... Acute Myeloid L... | Cyclophosphamid... Fludarabine (No... R-TM123 Allo-RevCAR01-T | 18 Years - | AvenCell Europe GmbH | |
| Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] | NCT06150040 | Acute Myeloid L... | NP137 Azacitidine Inj... Venetoclax | 65 Years - | Centre Leon Berard | |
| KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia | NCT04914845 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... | KPT-9274 | 18 Years - | University of Colorado, Denver | |
| Venetoclax to Augment Epigenetic Modification and Chemotherapy | NCT05317403 | Acute Myeloid L... Acute Myeloid L... | Venetoclax Azacitadine Vorinostat Cytarabine Fludarabine Filgrastim | 1 Year - 25 Years | Medical College of Wisconsin | |
| An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia | NCT06281847 | Acute Myeloid L... Acute Myeloid L... | CCTx-001 | 18 Years - | Advesya SAS | |
| Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 | NCT05949125 | Acute Myeloid L... Acute Myeloid L... | Cyclophosphamid... Fludarabine (No... R-TM123 Allo-RevCAR01-T | 18 Years - | AvenCell Europe GmbH | |
| Off-the-shelf CD123 CAR-NK for R/R AML | NCT06201247 | Acute Myeloid L... Acute Myeloid L... | JD123 injection | 18 Years - | Peking University People's Hospital | |
| Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] | NCT06150040 | Acute Myeloid L... | NP137 Azacitidine Inj... Venetoclax | 65 Years - | Centre Leon Berard | |
| A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML | NCT03690154 | Advanced Cancer Solid Tumors Acute Myeloid L... Acute Myeloid L... | FN-1501 | 18 Years - | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | |
| Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia | NCT05574608 | Acute Myeloid L... Acute Myeloid L... | CD123-CAR-NK ce... | 18 Years - | Affiliated Hospital to Academy of Military Medical Sciences | |
| A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | NCT05190471 | Acute Myeloid L... Acute Myeloid L... | BP1002; Liposom... Decitabine (in ... | 18 Years - | Bio-Path Holdings, Inc. | |
| Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] | NCT06150040 | Acute Myeloid L... | NP137 Azacitidine Inj... Venetoclax | 65 Years - | Centre Leon Berard | |
| AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT05211570 | Acute Myeloid L... Acute Myeloid L... Myelodysplastic... | AB8939 Azacitidine | 18 Years - | AB Science | |
| Natural Killer-cell Therapy for Acute Myeloid Leukemia | NCT04347616 | Acute Myeloid L... Acute Myeloid L... | UCB-NK cells IL-2 | 18 Years - | Radboud University Medical Center | |
| Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 | NCT05949125 | Acute Myeloid L... Acute Myeloid L... | Cyclophosphamid... Fludarabine (No... R-TM123 Allo-RevCAR01-T | 18 Years - | AvenCell Europe GmbH | |
| CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT06128044 | Acute Myeloid L... Acute Myeloid L... | CB-012 | 18 Years - | Caribou Biosciences, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
